Clinical trials: Cohort
Atopic Dermatitis
A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
The purpose of this research study is to determine whether the study drug, EDP1815, is safe and effective in the treatment of atopic dermatitis compared with placebo.
- Trial name
- NCT05121480
- Testing
- EDP1815
- Where
- 59 sites in United States, Australia and 4 more
- Volunteers
- 421 people
- Sponsor
- Evelo Biosciences, Inc.
Idiopathic Pulmonary Fibrosis
D2212C00002 J-Phase II Study
The purpose of the study is to evaluate the safety and tolerability of multiple-doses of tralokinumab in Japanese patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT02036580
- Testing
- tralokinumab cohort 1, tralokinumab cohort 2
- Where
- 5 sites in Japan
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Prevention of Oesophagus Cancer and Stomach Cancer
EffectiveNess of Low-dose Aspirin in Prevention of Cancer in the Stomach and Oesophagus (GastrointEstinal Cancer Prevention) - United Kingdom ("ENgAGE - UK"): Study to Evaluate the Risk of Cancer in the Stomach and Oesophagus Among New Users of Low-dose Aspirin Using the THIN Database in the UK
Researchers already did studies in low-dose Aspirin for the prevention of heart and blood vessels disease and for the prevention of cancer of the colorectum.
- Trial name
- ENgAGE-UK (NCT03743883)
- Testing
- Acetylsalicylic Acid(BAYE4465, Aspirin )
- Where
- United Kingdom
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)
This is a multi-center, Phase III study to evaluate the safety and tolerability of proposed dose conversion recommendations for RLS subjects converting from ropinirole immediate release to ropinirole controlled-release for RLS.
- Trial name
- NCT00256854
- Testing
- Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole CR 2 mg
- Where
- 30 sites in United States
- Volunteers
- 135 people
- Sponsor
- GlaxoSmithKline
General Population (no Specific Condition or Disease)
Evaluation of Reminder Strategies (Emails and Text Messages) to Increase Participation in the Le French Gut E-cohort
This study is a randomized controlled trial nested in the "Le French Gut" e-cohort aiming to test the efficacy of 4 reminder strategies (emails and/or SMS with standard and/or institutional wording) in increasing participation of…
- Trial name
- NCT07473466
- Testing
- 3 standard email reminders, 3 institutional email reminders, 3 SMS reminders
- Where
- France
- Volunteers
- 20,487 people, healthy volunteers welcome
- Sponsor
- SKEZI
Multiple Sclerosis
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
- Trial name
- NCT01892722
- Testing
- Interferon beta-1a, Fingolimod
- Where
- 73 sites in United States, Australia and 23 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Diagnosis, Gonorrhea
Susceptibility Testing In Neisseria Gonorrhoeae (STING) Study, Assessing the Performance of a New Rapid Test for Gonorrhoea Antibiotic Resistance, in a Cohort of 100 Culture Positive Neisseria Gonorrhoeae Infections
This study aims to validate a novel antibiotic susceptibility test (InSignia) for gonorrhoea in patient clinical samples. The hypothesis is that the InSignia test will be able to detect transcriptional responses after incubation…
- Conditions
- Diagnosis, Gonorrhea, Resistance Bacterial
- Trial name
- STING (NCT06352554)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SpeeDx Pty Ltd
Postoperative Nausea and Vomiting
Phase I PK and Safety Study of Ondansetron Inhalation Powder
The goal of this clinical trial is to learn if LPI-1503 (Ondansetron Inhalation Powder) can deliver ondansetron into blood through inhalation. It will also learn about the safety of LPI-1503.
- Trial name
- NCT07498751
- Testing
- LPI-1503, IV Ondansetron, Oral Ondansetron
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Luxena Pharmaceuticals, Inc.
Cancer, Multi Cancer Early Screening
The Jinling Cohort
The Jinling Cohort is a prospective, multicenter cohort study in which 15,000 eligible individuals aged 45-75 in Nanjing China will be enrolled.
- Conditions
- Cancer, Multi Cancer Early Screening, Liquid Biopsy
- Trial name
- NCT06011694
- Testing
- MERCURY test, health questionnaires and annual routine physical exams
- Where
- 2 sites in China
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Nanjing Shihejiyin Technology, Inc.
Neoplasms, Breast, Neoplasms, Lung
Study of ESG401 in Adults With Solid Tumors
The primary objective in Phase I is to evaluate the safety and tolerability of ESG401 as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer.
- Conditions
- Neoplasms, Breast, Neoplasms, Lung, Neoplasms,Colorectal, Neoplasms, Bladder
- Trial name
- NCT04892342
- Testing
- ESG401
- Where
- 3 sites in China
- Volunteers
- 156 people
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD/NASH in Chinese
Nonalcoholic fatty liver disease (NAFLD) is a progressive liver disease ranging from simple steatosis to cirrhosis of the liver.
- Trial name
- NCT03282305
- Volunteers
- 5,000 people
- Sponsor
- Great China Fatty Liver Consortium Limited
Healthy
A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants
The main purpose of this study is to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on single dose pharmacokinetic of LY4100511 (DICE-853) in healthy participants.
- Trial name
- NCT06345794
- Testing
- LY4100511 (DC-853), Itraconazole, Fluconazole
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Pulmonary Disease, Chronic Obstructive
A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)
Patients with chronic obstructive pulmonary disease (COPD) have elevated risk of mortality and cardiopulmonary events, particularly following exacerbations.
- Trial name
- SKOPOS:MAZI (NCT06744374)
- Testing
- BGF, MITT
- Where
- United States
- Volunteers
- 22,369 people
- Sponsor
- AstraZeneca
Treatment of Venous Thromboembolism in Cancer Patients
A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)
Patients with cancer are more likely than those without cancer to develop blood clots (deep vein thrombosis and pulmonary embolism), which are treated using blood thinners (anticoagulants).
- Trial name
- NCT05112666
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), other DOACs, LMWH
- Where
- United Kingdom
- Volunteers
- 2,601 people
- Sponsor
- Bayer
Safety
Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts
This Phase 1 study is designed to assess the safety and tolerability of single and multiple intravenous (IV) doses of MRX-8, to assess the pharmacokinetics of MRX-8 and its primary metabolite following single and multiple IV…
- Trial name
- NCT04649541
- Testing
- MRX-8
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- MicuRx
Asthma, Healthy Volunteers
Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With Asthma
This study evaluates the safety and tolerability of CHF10136 administered by inhalation in healthy adults and adults with asthma.
- Trial name
- NCT07851623
- Testing
- CHF10136
- Where
- 3 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
COVID-19
A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers
This is a prospective, epidemiological, cohort study to assess the feasibility of screening healthy asymptomatic workers for the presence of severe acute respiratory syndrome SARS-CoV-2 by pharyngeal swaps and serology at…
- Trial name
- NCT04405466
- Testing
- Blood sampling, Throat swab
- Where
- Germany
- Volunteers
- 417 people, healthy volunteers welcome
- Sponsor
- Miltenyi Biomedicine GmbH
Solid Tumor, Advanced Cancer
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered…
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer
- Trial name
- NCT04648254
- Testing
- Q702
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Qurient Co., Ltd.
Malaria, Vivax
A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate
This will be a single-centre, 5-cohort, randomized open-label, parallel-group study in healthy volunteer subjects. This study aims to provide sufficient pharmacokinetic (PK) evidence to support the safe usage of Tafenoquine (TQ)…
- Trial name
- NCT02184637
- Testing
- Tafenoquine, Dihydroartemisinin + Piperaquine tetraphosphate, Artemether + Lumefantrine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Plaque Psoriasis
Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis
This is an open-label, long-term safety study of roflumilast (ARQ-151) 0.3% cream in subjects with chronic plaque psoriasis involving up to 25% total Body Surface Area (BSA).
- Trial name
- NCT03764475
- Testing
- Roflumilast
- Where
- 30 sites in United States, Canada
- Volunteers
- 332 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.